Phaseline

Targets › NOD2

NOD2 (Nucleotide-binding oligomerization domain-containing protein 2): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Jul 2033.

Pattern recognition receptor (PRR) that detects bacterial peptidoglycan fragments and other danger signals and plays an important role in gastrointestinal immunity. Specifically activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan found in every bacterial peptidoglycan type. (UniProt, Q9HC29)

Open in Phaseline: the race on NOD2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Anna RaciborskaMifamurtide
Nucleotide-binding oligomerization domain-containing protein 2 other
NOD2Phase 2OsteosarcomaJul 2033
UNICANCERMifamurtide
Nucleotide-binding oligomerization domain-containing protein 2 other
NOD2Phase 2OsteosarcomaOct 2033

Conditions

Osteosarcoma (2)

Modalities

mixed (1), protein or peptide (1)

Companies

Anna Raciborska (1) UNICANCER (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.